Mining Gut Microbiota From Bariatric Surgery for MAFLD

The progression of metabolic dysfunction associated fatty liver disease (MAFLD) leads to steatohepatitis, liver fibrosis and hepatocellular carcinoma. Thus far, there have been no FDA-approved medications for MAFLD. Bariatric surgery (BS) has been found to improve insulin resistance, steatohepatitis...

全面介紹

書目詳細資料

發表在:	Frontiers in Endocrinology
Main Authors:	Wei-Kai Wu, Yi-Hsun Chen, Po-Chu Lee, Po-Jen Yang, Chin-Chen Chang, Kao-Lang Liu, Cheng-Chih Hsu, Chi-Chang Huang, Hsiao-Li Chuang, Lee-Yan Sheen, Chun-Jen Liu, Ming-Shiang Wu
格式:	Article
語言:	英语
出版:	Frontiers Media S.A. 2021-04-01
主題:	MAFLD bariatric surgery gut microbiota gut–liver axis multi-omics human microbiota associated mice
在線閱讀:	https://www.frontiersin.org/articles/10.3389/fendo.2021.612946/full